News|Articles|November 18, 2026

Perfuze Receives FDA Clearance for NeuroSheath 8F Long Sheath

Fact checked by: Isabella Ciccone, MPH
Listen
0:00 / 0:00

Key Takeaways

  • FDA 510(k) clearance enables an 8F long-sheath option to expand thrombectomy device compatibility, addressing limitations imposed by commonly used 6F sheaths.
  • NeuroSheath is engineered to support larger-bore aspiration, including compatibility with Millipede88 (0.088-inch ID) and its Corrugated technology, while maintaining maneuverability.
SHOW MORE

FDA 510(k) clearance adds an 8F neurovascular access sheath to Perfuze’s portfolio, designed to accommodate aspiration catheters up to 0.088 inches, including Millipede88.

Perfuze has received FDA 510(k) clearance for NeuroSheath, an 8 French (8F) long sheath designed for neurovascular access during mechanical thrombectomy procedures for acute ischemic stroke. The clearance completes the company’s stroke thrombectomy system, which includes aspiration and access catheters designed to support physicians throughout the procedure.1

A long sheath serves as the access point for neurovascular procedures, allowing other devices, including aspiration catheters used to remove clots, to pass through it. Its diameter can therefore influence which catheters physicians can use during thrombectomy. According to the company, larger-bore aspiration catheters generally require an 8F sheath, moving beyond the 6F sheaths commonly used by physicians has historically presented challenges related to ease of use and navigability.1

NeuroSheath is designed to accommodate catheters up to 8F and is compatible with Perfuze’s Millipede88 aspiration catheter, which features a 0.088-inch inner diameter and the company’s patented Corrugated technology. The sheath is intended to provide the capacity required for larger-bore aspiration catheters while maintaining maneuverability in challenging vascular anatomy, including a Type III aortic arch.1

“NeuroSheath is designed to give our team the versatility and flexibility to use any size aspiration catheter we’d like, right up to a super-bore 0.088-inch,” Sunil Sheth, MD, director of the Vascular and Interventional Neurology Division in the Department of Neurology at UTHealth Houston, said in a statement.1 “That way, the case decides the catheter, not the sheath. That’s what we’ve been looking for in a long sheath for neurovascular access.”

READ MORE: FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C

According to Perfuze, a neurovascular medical device company headquartered in Galway, Ireland, NeuroSheath will initially enter a limited market release at select US stroke centers, with broader US availability expected in 2027. The company plans to begin performing initial US cases ahead of the full commercial launch.

NeuroSheath joins the company’s existing Millipede88 and Millipede70 aspiration catheters and their corresponding Zipline88 and Zipline70 access catheters. Together, the devices are intended to provide an integrated system spanning vascular access through clot aspiration.

In a previous study, MARRS trial (NCT05714501), in which Millipede88 demonstrated near-complete or complete reperfusion, defined as modified Thrombolysis in Cerebral Infarction 2c or greater, following first-pass direct aspiration in 75% (42/56) of M1 occlusions included in the per-protocol analysis. The findings were reported for procedures using Millipede88 and did not involve NeuroSheath, according to the company.2

“Every stroke thrombectomy starts with access,” Wayne Allen, CEO of Perfuze, said in a statement.1 “NeuroSheath takes Perfuze from the clot in the brain back to the access point in the groin, where the procedure begins. Physicians now have a complete stroke system designed to work together. Our focus switches now to performing first US cases, then moving to a full market launch in 2027.”

Perfuze plans to showcase its neurovascular portfolio at the 2026 Society of Vascular and Interventional Neurology (SVIN) Annual Meeting, taking place November 18 to 20 in Las Vegas, Nevada.

Click here to view more of our FDA coverage.

REFERENCES
1. Perfuze Receives FDA Clearance for NeuroSheath™ 8F Long Sheath, Completing Its Stroke Thrombectomy System. Perfuze. News Release. November 18, 2026. Accessed November 18, 2026. https://www.businesswire.com/news/home/20261117035630/en/Perfuze-Receives-FDA-Clearance-for-NeuroSheath-8F-Long-Sheath-Completing-Its-Stroke-Thrombectomy-System
2. MARRS (NCT05714501), per-protocol analysis, M1 occlusions treated with Millipede88 first-pass direct aspiration, 42/56. NeuroSheath was not used in MARRS. Data on file CLIN087/TR336/TR352.

Related to this article